<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">Tocilizumab is a monoclonal antibody that targets the interleukin-6 receptor, which is the possible mediators of COVID-19 induced inflammation and cytokine storms 
 <xref rid="b0275" ref-type="bibr">[55]</xref>. It has potential possibly minor interaction with ciclosporin, tacrolimus, and sirolimus. Tocilizumab can reduce concentrations of calcineurin inhibitors with necessary drug level monitoring. Its use with chloroquine and hydroxychloroquine may have additive toxicity. Also, It may potentiate hematological toxicity of ribavirin and interferon-beta if used together as Tocilizumab has a myelosuppressive effect 
 <xref rid="b0285" ref-type="bibr">[57]</xref>.
</p>
